Russia faces serious decline in launches of new cancer drugs this year
The number of new cancer drugs are being launched in the Russian market is steadily declining these days, which is mainly due to the drop of local demand for them and tough business environment in Russia at present.
According to data from the Russian analyst Cursor, in 2025 only 81 new oncology drugs were registered in Russia, which is 21% less compared to 2024. The market, however, is growing this year, but only in value terms, which is mainly due to high inflation rates in the country. In the first half of 2026, the market reached 187.4 billion roubles ($2.15 billion), a 17% increase compared to the same period last year. From 2024 to August 1, 2026, 232 new anti-cancer drugs were registered in Russia, which is substantially lower, compared to previous years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze